Fanen Biotechnology key facts
- Manufacturer of tumor immunotherapy drugs aims to improve survival and quality of life for cancer patients.
- It has raised $14.8M; the latest was Later Stage VC in Apr 2025.
- Notable investors include Holley Group, Zhongshan Health Base Group, Beijing Huafang Investment Co., Panacea Capital (California), Yabao Pharmaceutical Group — 6 tracked in total.
- Status: Privately Held (backing).
- ·Watch Fanen Biotechnology: the Monday email on marks, rounds and moves
Fanen Biotechnology funding rounds
No funding rounds for Fanen Biotechnology are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Fanen Biotechnology investors
6 investors are on record for Fanen Biotechnology, including Holley Group, Zhongshan Health Base Group, Beijing Huafang Investment Co. and Panacea Capital (California).
About Fanen Biotechnology
Manufacturer of tumor immunotherapy drugs aims to improve survival and quality of life for cancer patients. The company's offerings feature personalized CAR-T, TCR-T cell therapies, tumor vaccines, and immune checkpoint inhibitors, combined with proprietary diagnostics and GMP-grade production capabilities, which help hospitals and cancer treatment centers access tailored and effective immunotherapies, enabling the precise and efficient treatment of solid tumors.
- Sector
- Healthcare
- HQ
- Guangzhou, China
- Founded
- 2016
- Website
- fineimmu.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
Fanen Biotechnology doesn't have a valuation on record yet — one is published once a priced round, a reported valuation, fund marks, or secondary prints surface in our sources. The rest of the record below builds toward it.